Innoviva, Inc. (NASDAQ:INVA - Get Free Report)'s share price reached a new 52-week low during trading on Monday. The stock traded as low as $18.60 and last traded at $18.56, with a volume of 232,807 shares. The stock had previously closed at $19.03.
Wall Street Analyst Weigh In
INVA has been the subject of a number of analyst reports. Zacks Research upgraded Innoviva from a "strong sell" rating to a "hold" rating in a report on Monday, August 31st. Weiss Ratings raised shares of Innoviva from a "hold (c+)" rating to a "buy (b)" rating in a research report on Monday, November 9th. Cantor Fitzgerald dropped their price objective on shares of Innoviva from $36.00 to $34.00 and set an "overweight" rating on the stock in a research note on Friday, August 7th. Wall Street Zen cut shares of Innoviva from a "buy" rating to a "hold" rating in a research report on Saturday, August 1st. Finally, Oppenheimer reduced their target price on shares of Innoviva from $35.00 to $34.00 and set an "outperform" rating on the stock in a research report on Thursday, November 5th. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, Innoviva currently has an average rating of "Moderate Buy" and an average target price of $39.00.
Read Our Latest Analysis on INVA
Innoviva Stock Down 2.9%
The company has a market capitalization of $1.31 billion, a price-to-earnings ratio of 9.26, a P/E/G ratio of 4.16 and a beta of 0.38. The company has a quick ratio of 14.58, a current ratio of 15.44 and a debt-to-equity ratio of 0.23. The firm has a 50 day moving average price of $20.70 and a two-hundred day moving average price of $21.85.
Innoviva (NASDAQ:INVA - Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported ($1.03) EPS for the quarter, missing the consensus estimate of $0.52 by ($1.55). The business had revenue of $106.12 million during the quarter, compared to analyst estimates of $115.31 million. Innoviva had a return on equity of 22.91% and a net margin of 44.13%. As a group, sell-side analysts expect that Innoviva, Inc. will post 1.52 earnings per share for the current year.
Institutional Investors Weigh In On Innoviva
Several hedge funds and other institutional investors have recently bought and sold shares of INVA. BlackRock Inc. acquired a new stake in Innoviva during the second quarter worth about $77,562,000. Dimensional Fund Advisors LP lifted its holdings in Innoviva by 1.7% in the first quarter. Dimensional Fund Advisors LP now owns 4,436,427 shares of the biotechnology company's stock worth $103,366,000 after acquiring an additional 76,026 shares during the last quarter. Bank of America Corp DE acquired a new position in Innoviva in the second quarter valued at approximately $37,873,000. Deutsche Bank AG acquired a new position in Innoviva in the second quarter valued at approximately $20,847,000. Finally, William Blair Investment Management LLC boosted its stake in Innoviva by 29.7% in the third quarter. William Blair Investment Management LLC now owns 832,881 shares of the biotechnology company's stock valued at $17,665,000 after acquiring an additional 190,705 shares during the period. 99.12% of the stock is currently owned by hedge funds and other institutional investors.
About Innoviva
(
Get Free Report)
Innoviva, Inc. is a biopharmaceutical company with two main areas of activity: royalty interests in respiratory medicines developed with GSK and the development and commercialization of specialty medicines. Its respiratory-related royalties include products such as Trelegy Ellipta, Anoro Ellipta and Breo Ellipta, which are used to treat chronic obstructive pulmonary disease and asthma and are marketed by GSK. Through its specialty therapeutics operations, Innoviva focuses on medicines for serious infections and other acute-care conditions.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Innoviva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Innoviva wasn't on the list.
While Innoviva currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.